Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.35 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.35 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 4/20 | 0.31 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.30 |
| ▸ | PYGM | P11217 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6832251 | 0.85 | RIPK1 (0.39) | AADATKYAT1KYAT3PYGLPYGM | |
| SCHEMBL6763244 | 0.81 | PYGL (0.35) | AADATKYAT1KYAT3KDM1ANPY1R | |
| SCHEMBL6762670 | 0.79 | AADAT (0.39) | AADATKDM1ANPY1RCCKBRPYGL | |
| SCHEMBL6763949 | 0.78 | BACE1 (0.39) | KDM1ANPY1RPYGLPYGMGAA | |
| SCHEMBL6762978 | 0.75 | AADAT (0.59) | AADATKYAT1KYAT3NPY1RGHSR | |
| SCHEMBL6763129 | 0.75 | KMT2A (0.42) | NPY1R | |
| SCHEMBL3781776 | 0.74 | CCKBR (0.39) | AADATKYAT1KYAT3KDM1ACCKBR | |
| SCHEMBL9886293 | 0.74 | KDM1A (0.38) | AADATKYAT1KYAT3KDM1ANPY1R | |
| SCHEMBL3774235 | 0.74 | HIF1A (0.36) | AADATKYAT1KYAT3PYGLPYGM | |
| SCHEMBL6763216 | 0.74 | RIPK1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | AADAT 2284/4885KYAT1 69/4885KYAT3 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.